It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Sputnik V is a two-dose shot and has an efficacy of 91.6% against COVID 19
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The company has strong product launches both in India and overseas
Anti-malaria API facility will be operational in 15-18 months
A treatment to prevent extreme symptoms and cut hospitalisation
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Subscribe To Our Newsletter & Stay Updated
